Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-18 1:46 pm Purchase | 2024-10-18 | 13G | Quince Therapeutics, Inc. QNCX | Genextra S.p.A. | 2,806,611 6.490% | 280,661 (+11.11%) | Filing History |
| 2025-02-14 4:29 pm Purchase | 2024-12-31 | 13G | Quince Therapeutics, Inc. QNCX | Sofinnova Capital VIII | 2,397,711 5.400% | 242,017 (+11.23%) | Filing History |
| 2024-11-14 4:00 pm Unchanged | 2024-09-30 | 13G | Quince Therapeutics, Inc. QNCX | TANG CAPITAL MANAGEMENT, LLC | 0 0.000% | 0 (Unchanged) | Filing History |
| 2024-11-13 9:17 pm Purchase | 2021-03-04 | 13D | Quince Therapeutics, Inc. QNCX | Lamond David | 4,460,154 10.100% | 2,411,216 (+117.68%) | Filing History |
| 2024-08-06 8:04 pm Sale | 2024-05-01 | 13G | Quince Therapeutics, Inc. QNCX | Sofinnova Capital VIII | 2,155,694 4.990% | -22,456 (-1.03%) | Filing History |
| 2024-02-14 4:00 pm Sale | 2023-12-31 | 13G | Quince Therapeutics, Inc. QNCX | TANG CAPITAL PARTNERS LP | 3,220,000 7.500% | -400,000 (-11.05%) | Filing History |
| 2024-02-12 09:00 am Purchase | 2023-12-31 | 13G | Quince Therapeutics, Inc. QNCX | Sofinnova Capital VIII | 2,178,150 5.100% | 2,178,150 (New Position) | Filing History |
| 2024-02-07 10:50 am Sale | 2023-12-31 | 13G | Quince Therapeutics, Inc. QNCX | BML Investment Partners, L.P. | 0 0.000% | -1,841,301 (Position Closed) | Filing History |
| 2023-12-14 5:51 pm Purchase | 2023-10-20 | 13G | Quince Therapeutics, Inc. QNCX | Genextra S.p.A. | 2,525,950 5.890% | 2,525,950 (New Position) | Filing History |
| 2023-07-17 11:07 am Purchase | 2023-07-06 | 13G | Quince Therapeutics, Inc. QNCX | BML Investment Partners, L.P. | 1,841,301 5.070% | 1,841,301 (New Position) | Filing History |
| 2023-03-31 4:00 pm Purchase | 2023-03-21 | 13G | Quince Therapeutics, Inc. QNCX | TANG CAPITAL PARTNERS LP | 3,620,000 9.980% | 3,620,000 (New Position) | Filing History |
| 2023-02-13 5:28 pm Sale | 2022-12-31 | 13G | Quince Therapeutics, Inc. QNCX | EPQ LLC CTYM PS | 1,576,720 4.400% | -1,286,376 (-44.93%) | Filing History |
| 2022-07-08 12:56 pm Sale | 2022-07-11 | 13G | Quince Therapeutics, Inc. QNCX | Capital World Investors | 0 0.000% | -2,501,882 (Position Closed) | Filing History |
| 2022-02-11 6:06 pm Sale | 2021-12-31 | 13G | Quince Therapeutics, Inc. QNCX | PFIZER INC PFE | 600,000 2.010% | -1,456,377 (-70.82%) | Filing History |
| 2022-02-11 2:48 pm Sale | 2022-02-14 | 13G | Quince Therapeutics, Inc. QNCX | Capital World Investors | 2,501,882 8.400% | -668,849 (-21.09%) | Filing History |
| 2022-02-11 12:22 pm Sale | 2022-02-14 | 13G | Quince Therapeutics, Inc. QNCX | Capital Research Global Investors | 0 0.000% | -2,605,753 (Position Closed) | Filing History |
| 2021-12-10 4:09 pm Unchanged | 2021-12-10 | 13G | Quince Therapeutics, Inc. QNCX | Capital International Investors | 1,462,465 4.900% | 0 (Unchanged) | Filing History |
| 2021-12-10 2:34 pm Sale | 2021-12-10 | 13G | Quince Therapeutics, Inc. QNCX | Capital International Investors | 1,462,465 4.900% | -1,514,024 (-50.87%) | Filing History |
| 2021-10-08 12:10 pm Unchanged | 2021-10-12 | 13G | Quince Therapeutics, Inc. QNCX | Capital International Investors | 2,976,489 10.000% | 0 (Unchanged) | Filing History |
| 2021-10-08 12:03 pm Purchase | 2021-10-12 | 13G | Quince Therapeutics, Inc. QNCX | Capital International Investors | 2,976,489 10.000% | 396,034 (+15.35%) | Filing History |